Discovering The Potential of IGHV2-70 as A Drug Target Or Biomarker

Target Name: IGHV2-70

NCBI ID: G28454

IGHV2-70

Other Name(s): immunoglobulin heavy variable 2-70 | Immunoglobulin heavy variable 2-70 | IGHV270 | VH

Discovering The Potential of IGHV2-70 as A Drug Target Or Biomarker

IGHV2-70, also known as human IgG variable region fragment 2-70, is a single-chain antibody fragment that is derived from the heavy variable region of human immunoglobulin (IgG). It is a glycoprotein that consists of 116 amino acids and has a molecular weight of 18 kDa.

IGHV2-70 is a well-known protein that is expressed in various tissues and organs, including the liver, spleen, and lymph nodes. It is also expressed in the blood and plasma, and it has been identified as a potential drug target in the treatment of various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

One of the key reasons for the interest in IGHV2-70 is its potential as a drug target. IGHV2-70 has been shown to play a role in a number of cellular processes, including inflammation, antigens presentation, and immune surveillance. It is also involved in the regulation of cellular processes that are important for the development and progression of certain diseases, including cancer.

Studies have shown that IGHV2-70 can interact with a number of different molecules, including transcription factors, cytokines, and proteins involved in the immune response. This suggests that IGHV2-70 may be a useful biomarker or drug target in the treatment of diseases that are characterized by inflammation or immune dysfunction.

In addition to its potential as a drug target, IGHV2-70 is also of interest as a potential biomarker for the diagnosis and monitoring of certain diseases. For example, IGHV2-70 has been shown to be expressed in the blood cells of patients with certain types of cancer, including breast cancer and lung cancer. This suggests that IGHV2-70 may be a useful diagnostic tool for these diseases, and that its levels may be able to be used as a marker for disease progression or response to treatment.

Another potential application of IGHV2-70 is its use as an therapeutic agent. Studies have shown that IGHV2-70 can be used to treat a variety of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. For example, IGHV2-70 has been shown to be effective in treating certain types of cancer, including breast cancer and lung cancer, by triggering an immune response against the cancer cells.

In addition to its potential as a therapeutic agent, IGHV2-70 is also of interest as a potential biomarker for the monitoring of disease progression and response to treatment. For example, IGHV2-70 has been shown to be expressed in the blood cells of patients with certain types of cancer, including breast cancer and lung cancer. This suggests that IGHV2-70 may be a useful marker for the monitoring of disease progression and response to treatment in these diseases.

Overall, IGHV2-70 is a fascinating protein that has the potential to be a drug target or biomarker in the treatment of various diseases. Further research is needed to fully understand its role in these processes and to develop effective treatments based on its properties.

Protein Name: Immunoglobulin Heavy Variable 2-70

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV2-70 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV2-70 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets